Recurrent Non-small Cell Lung Cancer Terminated Phase 2 Trials for Bortezomib (DB00188)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00040768Bortezomib in Treating Patients With Advanced Non-small Cell Lung CancerTreatment